Syncromune Revenue and Competitors
Estimated Revenue & Valuation
- Syncromune's estimated annual revenue is currently $4.8M per year.
- Syncromune's estimated revenue per employee is $155,000
- Syncromune's total funding is $130M.
Employee Data
- Syncromune has 31 Employees.
- Syncromune grew their employee count by 41% last year.
Syncromune's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Founder and Executive Chairman | Reveal Email/Phone |
2 | President & CEO | Reveal Email/Phone |
3 | Chief Business Officer | Reveal Email/Phone |
4 | Chief Regulatory & Compliance Officer | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Chief Financial Officer | Reveal Email/Phone |
7 | Chief Scientific Officer | Reveal Email/Phone |
8 | Chief Regulatory Officer | Reveal Email/Phone |
9 | EVP, Corporate Communications | Reveal Email/Phone |
10 | SVP Human Resources | Reveal Email/Phone |
Syncromune Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $17.5M | 113 | 14% | N/A | N/A |
#2 | $1.9M | 12 | 0% | N/A | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $4.5M | 29 | 21% | N/A | N/A |
#5 | $4.8M | 31 | 11% | N/A | N/A |
#6 | $3.1M | 20 | N/A | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $1.1M | 7 | 0% | N/A | N/A |
#9 | $2.6M | 17 | 6% | N/A | N/A |
#10 | $0.6M | 4 | -56% | N/A | N/A |
What Is Syncromune?
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ platform therapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend with immune memory. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.
keywords:N/A
$130M
Total Funding
31
Number of Employees
$4.8M
Revenue (est)
41%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Fort Lauderdale
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.1M | 31 | -6% | N/A |
#2 | $8.1M | 31 | N/A | N/A |
#3 | $5.5M | 31 | 3% | N/A |
#4 | $6.7M | 31 | 15% | N/A |
#5 | $2.5M | 31 | -3% | N/A |